Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferon gamma-mediated prevention of tumor progression in a mouse model of multiple myeloma.
Kellermayer Z, Tahri S, de Jong MME, Papazian N, Fokkema C, Stoetman ECG, Hoogenboezem R, van Beek G, Sanders MA, Boon L, Den Hollander C, Broijl A, Sonneveld P, Cupedo T. Kellermayer Z, et al. Among authors: broijl a. Hemasphere. 2024 Dec 2;8(12):e70047. doi: 10.1002/hem3.70047. eCollection 2024 Dec. Hemasphere. 2024. PMID: 39624831 Free PMC article.
Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial.
Mai EK, Nogai A, Lokhorst HM, van der Holt B, Zweegman S, Weisel KC, Croockewit S, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Bos GMJ, Brossart P, Ypma P, Hanoun C, Bertsch U, Hielscher T, Salwender HJ, Scheid C, Goldschmidt H, Sonneveld P. Mai EK, et al. Among authors: broijl a. Hemasphere. 2024 Nov 20;8(11):e70052. doi: 10.1002/hem3.70052. eCollection 2024 Nov. Hemasphere. 2024. PMID: 39569355 Free PMC article. No abstract available.
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, van de Donk NWCJ, Katodritou E, Schjesvold F, Balari AS, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P. Sonneveld P, et al. Among authors: broijl a. Future Oncol. 2024;20(38):3043-3063. doi: 10.1080/14796694.2024.2394323. Epub 2024 Sep 17. Future Oncol. 2024. PMID: 39287147
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon S, Abrahamsen IW, Baz R, Broijl A, Chen C, Jagannath S, Raje N, Scheid C, Delforge M, Benjamin R, Pabst T, Iida S, Berdeja J, Giralt S, Truppel-Hartmann A, Chen Y, Zhong X, Wu F, Piasecki J, Eliason L, Dhanda D, Felten J, Caia A, Cook M, Popa McKiver M, Rodríguez-Otero P. Ailawadhi S, et al. Among authors: broijl a. Blood. 2024 Dec 5;144(23):2389-2401. doi: 10.1182/blood.2024024582. Blood. 2024. PMID: 39197072 Clinical Trial.
HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients.
Minnema MC, Nasserinejad K, Hegenbart U, Ypma PF, Wu KL, Kersten MJ, Croockewit S, Zweegman S, Tick L, Broijl A, Koene H, Bos GMJ, Sonneveld P, Schönland SO. Minnema MC, et al. Among authors: broijl a. EJHaem. 2024 Jun 17;5(4):815-819. doi: 10.1002/jha2.918. eCollection 2024 Aug. EJHaem. 2024. PMID: 39157610 Free PMC article.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Zweegman S, Caillon H, Caillot D, Avet-Loiseau H, Delforge M, Dejoie T, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Schiano de Colella JM, van de Donk NW, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Hua W, Wang J, Tuozzo A, de Boer C, Rowe M, Vanquickelberghe V, Carson R, Vermeulen J, Corre J, Sonneveld P; Intergroupe Francophone du Myélome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators. Moreau P, et al. Among authors: broijl a. Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15. Lancet Oncol. 2024. PMID: 38889735 Clinical Trial.
An IL-1β-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma.
de Jong MME, Fokkema C, Papazian N, Czeti Á, Appelman MK, Vermeulen M, van Heusden T, Hoogenboezem RM, van Beek G, Tahri S, Sanders MA, van de Woestijne PC, Gay F, Moreau P, Büttner-Herold M, Bruns H, van Duin M, Broijl A, Sonneveld P, Cupedo T. de Jong MME, et al. Among authors: broijl a. Nat Immunol. 2024 May;25(5):820-833. doi: 10.1038/s41590-024-01808-x. Epub 2024 Apr 10. Nat Immunol. 2024. PMID: 38600356
Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research.
Oerlemans S, De Rooij BH, Bennink C, Bullinger L, Broijl A, D'Agostino M, Laane E, Lupo-Stanghellini MT, Perrot A, Wester R, Cursaru V, Scheurer H, Vesseur J, Dalal M, Sen R, Stamm T, Ludwig H, Sonneveld P. Oerlemans S, et al. Among authors: broijl a. Haematologica. 2024 Jun 1;109(6):1956-1959. doi: 10.3324/haematol.2023.284282. Haematologica. 2024. PMID: 38299690 Free PMC article. No abstract available.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. Among authors: broijl a. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
55 results